Figure 3
From: Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics
Correlation analysis between basal active TGF-β serum levels and fasting blood glucose, insulin and proinsulin levels. Basal active TGF-β serum levels of T2DM patients treated with metformin and sulfonylurea (S+M), insulin glargine (G+M) or a DPP-4 inhibitor (D+M) as well as of non-diabetic controls (C) were correlated with basal (a) blood glucose levels, (b) insulin levels, and (c) proinsulin levels.